Episode Details

When a loved one faces metastatic cancer, the outlook can be challenging, with significantly low survival rates for conditions like lung cancer and breast cancer. 

Dr. Prato highlights the stark reality of cancer cells spreading, contrasting the American Cancer Society's optimistic 70% overall survival rate with the grim statistics for a cancer patient with advanced disease. Understanding the nuances of cancer treatment and its efficacy against metastasis is crucial.

🎯 What You’ll Learn in This Episode
• What the “70% cancer survival” statistic actually represents
• Why early-stage and metastatic cancers have very different outcomes
• Why stage-specific survival data matters for patients
• How early detection dramatically improves outcomes
• What multi-cancer early detection testing is
• How multi-omics testing helps guide treatment decisions
• The role of immune profiling in cancer treatment strategies
• Why personalized oncology approaches are growing in importance

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Cancer statistics describe populations — but treatment decisions must focus on the individual.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493